Global Market for Next Generation Immune Checkpoint Inhibitors and Stimulators Market 2020: Profiles of Leading Players Including AbbVie, Astellas Pharmaceuticals, AstraZeneca and Takeda Pharmaceutical
Dublin, May 29, 2020 (GLOBE NEWSWIRE) -- The "Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients' quality of life.
There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb's Yervoy (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1/PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.
This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
A detailed assessment of the current market landscape, including information on drug developer(s), phase of development of lead candidates, target immune checkpoints, their respective mechanisms of action, type of therapeutic modality used, route of administration, target disease indication, target therapeutic area and type of therapy.
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant parameters.
Detailed profiles of developers of next generation immune checkpoint modulators, featuring an overview of the company, its financial information, a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects, in the period between 2016 and 2019.
An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements, product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant types of deals.
An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for next generation immune checkpoint therapy development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of grants and number of publications [B] a five-dimensional spider-web analysis, highlighting the most popular immune checkpoint targets.
Analysis of big biopharma players in this domain, featuring a heat map based on parameters, such as number of therapies under development, target disease indications, partnership activity and target portfolio.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES
5. MARKET LANDSCAPE: THERAPIES TARGETING CD47
6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB
7. CLINICAL TRIAL ANALYSIS
8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS
9. ACADEMIC GRANTS ANALYSIS
10. PARTNERSHIPS AND COLLABORATIONS
11. TARGET COMPETITIVENESS ANALYSIS
12. BIG PHARMA INITIATIVES
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. CONCLUDING REMARKS
A selection of companies mentioned include:
AbbVie
AbClon
Abeome
ABL Bio
Abpro
Acerta Pharma
Aduro Biotech
Allergan
Alligator Bioscience
Alpine Immune Sciences
ALX Oncology
Arch Oncology
Arcus Biosciences
ArQule
Astellas Pharma
Astex Pharmaceuticals
AstraZeneca
Atridia
BIOCAD
bluebird bio
Boehringer Ingelheim
Bristol-Myers Squibb
Calithera Biosciences
CALIXAR
CASI Pharmaceuticals
Catalent Biologics
Daiichi Sankyo
Genosco
GigaGen
Gilead Sciences
Glaxosmithkline
Glenmark
Glycotope
Hanmi Pharmaceutical
HanX Biopharmaceuticals
Heat Biologics
Hrain Biotechnology
Hummingbird Bioscience
IGM Biosciences
I-Mab Biopharma
ImmuneOnco Biopharmaceuticals
ImmuNext
Merck
Merus
Moderna
Molecular Partners
MorphoSys
Navigen
Pieris Pharmaceuticals
Pinze Lifetechnology
Roche
Rubius Therapeutics
Sanofi
Sanquin
Shire
Surface Oncology
Takeda Pharmaceutical
TESARO
Trellis Biosciences
Xencor
XOMA
Y-Biologics
Zai Lab
Zymeworks
For more information about this report visit https://www.researchandmarkets.com/r/oodo57
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900